LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Aktien・Kura Oncology Inc

Kura Oncology Inc

Geschlossen

BrancheGesundheitswesen

8.81 1.85

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.58

Max

8.99

Schlüsselkennzahlen
By Trading Economics
Einkommen	7.7M -73M
Verkäufe	929K 18M
EPS	-0.828
Gewinnspanne	-401.495
Angestellte	260
EBITDA	7.4M -78M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+228.39% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-84M 760M
Vorheriger Eröffnungskurs	6.96
Vorheriger Schlusskurs	8.81

Nachrichtenstimmung

By Acuity

100%

315 / 344 Ranking in Healthcare

Kura Oncology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Juni 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9. Juni 2026, 23:45 UTC

Akquisitionen, Fusionen, Übernahmen

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9. Juni 2026, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9. Juni 2026, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9. Juni 2026, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9. Juni 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9. Juni 2026, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Additional Investment Makes It Largest Shareholder in Element

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9. Juni 2026, 20:51 UTC

Ergebnisse

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Juni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Juni 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9. Juni 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9. Juni 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9. Juni 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9. Juni 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9. Juni 2026, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9. Juni 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9. Juni 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9. Juni 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9. Juni 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9. Juni 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9. Juni 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

9. Juni 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9. Juni 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer-Vergleich

Kursveränderung

Kura Oncology Inc Prognose

Kursziel

By TipRanks

228.39% Vorteil

12-Monats-Prognose

Durchschnitt 28.11 USD 228.39%

Hoch 40 USD

Tief 15 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Kura Oncology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Kura Oncology Inc – Dist abgegeben haben.

Stimmung

By Acuity

315 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.